Live
BioPharma DiveIncyte to buy blood disorder drug in possibly $2B dealFierceBiotechClinical-stage cancer biotech Treeline sees path to public markets via reverse mergerFierceBiotechADA: Dexcom CGM shows benefit in non-insulin diabetes patientsBioPharma DiveJ&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1BEndpoints NewsTreeline to go public via reverse merger with Standard BioToolsBioPharma DiveADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ optionFierceBiotechResmed snaps up Noctrix Health in $340M sleep tech dealBioWorldBiggest gainers and losers for June 1-5, 2026Endpoints NewsJ&J makes $1B move for Firefly Bio, Carolyn Bertozzi's twist on ADCs in KRAS fieldFierceBiotechJ&J makes $1B upfront bet on emerging DAC space by netting Firefly BioEndpoints NewsGSK inks multi-target pact with Engitix; Sangamo considers strategic optionsEndpoints NewsTango plans Phase 3 pancreatic cancer study after combo success
Endpoints News 18 déc. 2025

Atavistik raises $120M for bleeding disorder, blood cancer drugs

Atavistik raises $120M for bleeding disorder, blood cancer drugs

Original
Contenu indisponible. Consultez la source originale.